IFN-beta twice a daily/Ribavirin combination therapy following PEG-IFN-alfa/Ribavirin therapy for chronic hepatitis C patients: efficacy and safety
Not Applicable
- Conditions
- chronic hepatitis C
- Registration Number
- JPRN-UMIN000003549
- Lead Sponsor
- kanazawa university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
contraindication of IFN/Ribavirin tharapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy
- Secondary Outcome Measures
Name Time Method